All News

EULAR19.abstract.jpg (keep)

Featured Abstracts from Industry at EULAR 2021

Jack Cush, MD

Many great presentations this week at EULAR 2021 will feature industry sponsored clinical trials and reports.  Often these become the pivotal studies for regulatory approval and the annual congresses are their first look.

Read Article
RheumNow Podcast square

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Vaccine2.jpg (keep)

Methotrexate Impairs COVID Vax Response

MedPage Today

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.

Read Article
pills-3d-render-5-1165365.jpg

Triple DMARD Therapy Bested by Biologics in Swedish Registry

Jack Cush, MD

The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.

Read Article
Covid lung pneumonia corona (keep)

Tocilizumab Augmented Efficacy in COVID-19 Pneumonia with High CRP

Jack Cush, MD

JAMA Internal Medicine report an analysis of recent and composite trial data suggesting that tocilizumab (TCZ) therapy in COVID-19–associated pneumonia patients with high CRP levels is likely to be effective.

Read Article
healthcare.costs_.jpg

Congress Slams AbbVie Over Price Hikes, 'Frivolous' Patents

MedPage Today

House lawmakers on both sides of the aisle pummeled AbbVie CEO Richard Gonzalez for raising the price of two widely used drugs and for the company's "legally questionable" tactics to head off competition from biosimilars, despite pulling in healthy profits.

Read Article
COVID.Flu_.Virus_.jpg (keep)

Factors Associated with COVID-19 Deaths in Rheumatic Patients

Jack Cush, MD

Analysis of data from the COVID-19 Global Rheumatology Alliance shows that rheumatic diseases infected with COVID-19 had a greater risk of death with age, comorbidities, high disease activity and few specific therapies.

Read Article
RheumNow Podcast square

RheumNow Podcast – Myth Busters (5.21.2021)

Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
infx.pneumonia.jpg

Lower Rates of Serious Infection with Ustekinumab in Psoriatic Disease

MedPage Today

Patients with psoriasis or psoriatic arthritis who were being treated with ustekinumab (Stelara) had lower rates of serious hospitalized infections than patients receiving other biologics or small molecule therapies, a study utilizing data from two commercial claims databases found.

Read Article
Yes more lab abnormalities in #Upadactinib vs #Adalimumab in RA RCTs including cytopenias, transaminitis but not creatinine @RheumNow @eular_org #EULAR2021 but no diff in treatmt emergent Adverse events abst OP0128 Yes do labs when on #Upadacitinib https://t.co/5ypKGxuE3U https://t.co/XRjr0gDnIT

Links:

Janet Pope Janetbirdope ( View Tweet)
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden in PsA patients. #EULAR2021 @RheumNow Poster #POS0194 https://t.co/FaIZ7LcoNj
Dr. Rachel Tate uptoTate ( View Tweet)
The post hoc EXCEED analysis showed similar efficacy of SEC and ADA with respect to enthesitis burden. What drug class do you choose as first line therapy for your PsA patients with prominent enthesitis? #EULAR2021 @RheumNow

Dr. Rachel Tate uptoTate ( View Tweet)

Lifetime risk of HZ is 30%! ⬆️ in pts with immune diseases or immunesuppression. All #JAKI ⬆️ risk maybe doubling but NNH & NNT give context. UPA Rx in active RA -20 more pts in remission vs 1 excess HZ if comparing UPA to ADA in RA @RheumNow #EULAR2021 AbbVie symposium https://t.co/14i0IsIpzs
Janet Pope Janetbirdope ( View Tweet)
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern). https://t.co/lmXBbJz6ts

Links:

Dr. John Cush RheumNow ( View Tweet)

Top May Tweet: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w

Links:

Dr. John Cush RheumNow ( View Tweet)

News: Triple DMARD Therapy Bested by Biologics in Swedish Registry The Swedish Register compared outcomes of 1502 RA patients initiating either biologics plus MTX or triple therapy and showed similar rates of sustained remission. https://t.co/7JJxGF1tHz https://t.co/ht6kAsJkb9

Links:

Dr. John Cush RheumNow ( View Tweet)
Italian study of 1216 rheumatic pts on DMARDs, Biologics underwent HBV testing. They found HBV in 15.7% (chronic infection: 0.4%, resolved infection: 12.6%, anti-HBc positivity alone: 2.6%). HBV reactivation occurred in 6.2%. Only 1 acute hepatitis https://t.co/WofN4rqq6p

Links:

Dr. John Cush RheumNow ( View Tweet)

Listen to the latest RheumNow podcast--Myth Busters. Jack Cush discusses the latest rheum news on the site. Download wherever podcasts are available. https://t.co/q7FZTDo0BL https://t.co/fxGnyChzSO

Links:

Dr. John Cush RheumNow ( View Tweet)
#LupusAwarenessMonth Dr. Mike Putman - TULIP Trials - Anifrolumab in SLE https://t.co/cqZiulDMFm https://t.co/Vo17RfBOSk

Links:

Dr. John Cush RheumNow ( View Tweet)
Real world study of 21 GCA patients over age 80 yrs taking tocilizumab. (for GC-sparing in 14, relapsing Dz in 8, severity in 4, DMARD failure in 4). 8 [2–21] months post-TCZ, 67% were off GCs. AE included 4 Hi Chol, 3 SIE, 2 cytopenia, 1 hi LFTs https://t.co/ER0ROQw4ma

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×